Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 506.01m |
Free float | 487.96m |
P/E (TTM) | -- |
Market cap | 172.04m USD |
EPS (TTM) | -1.31 USD |
Data delayed at least 20 minutes.
More ▼
Announcements
- Independent Directors of 23andMe Resign from Board
- 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
- 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
- One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
- 23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
- Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
- 23andMe Reports First Quarter Fiscal 2025 Financial Results
- 23andMe Special Committee responds to CEO’s take-private proposal
- 23andMe Announces CEO’s Take-Private Proposal
- 23andMe to Report Q1 FY2025 Financial Results
More ▼